Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Gregory L. Verdine
AddedFeb 13, 2024
UpdatedMay 31, 2026
Gregory L. Verdine

Gregory L. Verdine

Co-Founder, Wave Life Sciences

CrunchbaseLinkedInThe Org

Gregory L. Verdine's Career

Wave Life Sciences
Wave Life Sciences

Cambridge, MA, US

Co-Founder
LifeMine Therapeutics
LifeMine Therapeutics

Cambridge, MA, US

CEO· C-Suite · Management
Fog Pharmaceuticals
Fog Pharmaceuticals

Cambridge, MA, US

Co-Founder
Enanta Pharmaceuticals
Enanta Pharmaceuticals

Watertown, MA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Gregory L. Verdine's Career

Wave Life Sciences
Wave Life Sciences
Public$324M2172012Cambridge, MA, US
Co-Founder

Leadership at Wave Life Sciences

Mark H N CorriganMark H N CorriganBoard Member
Christian HenryChristian HenryBoard Member
Paul BolnoPaul BolnoCEO
Takeshi WadaTakeshi WadaCo-Founder
Ken TakanashiKen TakanashiBoard Member
Adrian RawcliffeAdrian RawcliffeBoard Member

Similar to Wave Life Sciences

Ionis PharmaceuticalsIonis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796
Twist BioscienceTwist BioscienceSan Francisco, CA, USSynthetic DNAest. 2013Twist BioscienceSan Francisco, CA, US · est. 2013

Twist Bioscience: A leading US biotech firm specializing in synthetic DNA for diverse applications.

Public · $553.1M989
Orbital TherapeuticsOrbital TherapeuticsCambridge, MA, USMedicines, RNA Therapiesest. 2022Orbital TherapeuticsCambridge, MA, US · est. 2022

Orbital Therapeutics: Advancing global health with innovative RNA-based medicines.

Series A · $270M33
ReviR TherapeuticsReviR TherapeuticsSan Francisco, CA, USMedicines, Therapeuticsest. 2021ReviR TherapeuticsSan Francisco, CA, US · est. 2021

ReviR Therapeutics: A genomics-based platform for developing innovative RNA-targeting medicines.

Seed · $20M27
LifeMine Therapeutics
LifeMine Therapeutics
Series C$295M1362016Cambridge, MA, US
CEO· C-Suite · Management

Leadership at LifeMine Therapeutics

Rick KlausnerRick KlausnerBoard Member
Krishna YeshwantKrishna YeshwantBoard Member
Edward HuEdward HuBoard Member
Jen JarrettJen JarrettBoard Member
Bill KaelinBill KaelinBoard Member
Fog Pharmaceuticals
Fog Pharmaceuticals
Series D$385.3M1472015Cambridge, MA, US
Co-Founder

Leadership at Fog Pharmaceuticals

Barbara WeberBarbara WeberBoard Member
Corey GoodmanCorey GoodmanBoard Member
Weiqing ZhouWeiqing ZhouCo-Founder
Edward FitzgeraldEdward FitzgeraldBoard Member
Jeffrey LeerinkJeffrey LeerinkBoard Member

Similar to Fog Pharmaceuticals

Foghorn TherapeuticsFoghorn TherapeuticsCambridge, MA, USDrug Development, Pharmaceuticalsest. 2015Foghorn TherapeuticsCambridge, MA, US · est. 2015

Foghorn Therapeutics Inc., a US-based pharmaceutical company, innovates novel drugs for cancer and serious disorders.

Public · $111M161
Camino PharmaCamino PharmaSan Diego, CA, USCancer Treatment, Drug Developmentest. 2014Camino PharmaSan Diego, CA, US · est. 2014

Camino Pharma: A tech startup pioneering first-in-class cancer and CNS disorder therapies.

Seed · $13.7M3
Tigris PharmaceuticalsTigris PharmaceuticalsBonita Springs, FL, USCancer Treatmentsest. 2005Tigris PharmaceuticalsBonita Springs, FL, US · est. 2005

Tigris Pharmaceuticals: Innovating biopharmaceutical solutions for cancer and other medical needs.

Series C · $32.5M6
Frontier MedicinesFrontier MedicinesSouth San Francisco, CA, USPrecision Medicine, Therapeuticsest. 2018Frontier MedicinesSouth San Francisco, CA, US · est. 2018

Frontier Medicines, a US-based precision medicine firm, pioneers in developing treatments for previously undruggable diseases.

Series B · $244M128
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Public$84.6M1601995Watertown, MA, US
Founder

Leadership at Enanta Pharmaceuticals

Terry VanceTerry VanceBoard Member
Jay R. LulyJay R. LulyCEO
Kristine PetersonKristine PetersonBoard Member
Mark FolettaMark FolettaBoard Member
Bruce CarterBruce CarterBoard Member

Similar to Enanta Pharmaceuticals

Anthera PharmaceuticalsAnthera PharmaceuticalsHayward, CA, USPharmaceuticalsest. 2004Anthera PharmaceuticalsHayward, CA, US · est. 2004

Anthera Pharmaceuticals: A US biopharma firm specializing in inflammation and autoimmune disease treatments.

Public · $101.5M21
Entrada TherapeuticsEntrada TherapeuticsBoston, MA, USBiologics, Therapeuticsest. 2016Entrada TherapeuticsBoston, MA, US · est. 2016

Entrada Therapeutics: A global biotech firm developing intracellular biologics for devastating diseases.

Public · $201.6M130
Theravance BiopharmaTheravance BiopharmaSouth San Francisco, CA, USDrug Developmentest. 1996Theravance BiopharmaSouth San Francisco, CA, US · est. 1996

Theravance Biopharma develops and commercializes small molecule medicines for various therapeutic areas.

Public · $663.2M111

Gregory L. Verdine's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Gregory L. Verdine

Benjamin CravattBenjamin CravattCo-Founder · Boundless BioSamir MitragotriSamir MitragotriFounder · i2o TherapeuticsValerie DaggettValerie DaggettFounder · AltPepAlexander KlibanovAlexander KlibanovFounder · PulmatrixDavid R. LiuDavid R. LiuCo-Founder · Beam TherapeuticsPaul SchimmelPaul SchimmelBoard Member · Longwood Fund